TETRA Technologies, Inc.

Tetra Technologies is an interesting investment opportunity, given the sizable share price pullback and its potential for growth in the next few years. TTI's innovations and services are poised for increased demand as the industry tackles harder-to-recover reserves and aging fields. Despite 8% revenue growth in Q2, net income declined 10%, but interest expense remains comfortably low at 1.8% of revenues.

San Diego, California--(Newsfile Corp. - September 3, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQB: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing sulfur-based therapeutics for rare diseases, today announced that it has engaged Brisco Capital Partners Corp. ("Brisco") to provide investor relations services. Brisco will assist the Company in expanding communications with shareholders, investors and the broader investment community to increase awareness of Thiogenesis and its development programs.

SPRING, Texas, Sept. 2, 2026 /PRNewswire/ -- TETRA Technologies, Inc. ("TETRA" or the "Company") (NYSE: TTI) announced that Brady Murphy, Chief Executive Officer, and Kurt Hallead, Treasurer and VP of Investor Relations, will be meeting with institutional investors at the following conferences: September 9, 2026: Barclays 40th Annual Energy-Power Conference (NY, NY) September 10, 2026: Jefferies Renewables, Clean Energy and E&C Conference (NY, NY) TETRA's most recent presentation is available on its Investor Relations site.

Technip Energies (OTCMKTS:THNPY - Get Free Report) and Tetra Technologies (NYSE: TTI - Get Free Report) are both energy companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, dividends, profitability, valuation and risk. Valuation and Earnings This table compares Technip Energies